SElinexor

Karyopharm Therapeutics (NASDAQ: KPTI) shares spiked higher following an apparent leak of the company's website for Selinexor went live. The website is behind a firewall. Karyopharm shares traded up 36.03% at $8.90 before being halted at 11:06 a.m. ET. $KPTI Karyopharm Therapeutics Xpovio (...

The FDA went overdrive in the month of June, deciding on several regulatory applications before the July 4 holiday. There were favorable outcomes as well as disappointments. Acer Therapeutics Inc (NASDAQ: ACER) went about a freefall, shedding about 79% in a single session after the FDA issued a...

Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares were nosediving on roughly 11 times their average volume Friday following the release of the FDA briefing document prepared for review by the adcom panel that is evaluating the company's new drug application for selinexor. What Happened...

Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced that the interim analysis of its Phase 2 SOPRA study of selinexor monotherapy in acute myelogenous leukemia (AML) failed to meet the primary endpoint of overall survival (OS). Wedbush’s David M. Nierengarten maintaisd an Outperform rating...

Jefferies has upgraded Karyopharm Therapeutics Inc (NASDAQ: KPTI) to Buy from Hold as it expects the upcoming STORM data to support Selinexor's potential in refractory multiple myeloma (MM), potentially driving near-term share upside. The brokerage still sees potential for meaningful revenues,...